Janssen is partnering with Bristol-Myers Squibb to study a promising new combination treatment for several types of cancer.
The companies will collaborate to assess a combination of the CD38-directed cytolytic antibody Darzalex, developed by Janssen, and Bristol-Myers Squibb's checkpoint inhibitor Opdivo in phase Ib/II clinical studies in multiple myeloma and several solid tumour types.
“Janssen and Bristol-Myers Squibb are allying on a study assessing a new combination of Darzalex and Opdivo.“
The multiple myeloma study will evaluate the safety and tolerability of the combination with or without pomalidomide and dexamethasone in relapsed and refractory multiple myeloma, while the solid tumour studies will assess the drug's benefits for cancer types including non-small cell lung, head and neck, pancreatic, colorectal and triple-negative breast cancers.
Additional tumour types may also be evaluated, with studies expected to start this year.
Dr Peter Lebowitz, global oncology head of Janssen, said: "This agreement allows us to extend our footprint in immuno-oncology and will be a significant addition to the growing body of clinical data for daratumumab in combination with other novel agents, in a variety of tumour types."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical